TRM9 Antibody

What is TRM9 and what is its primary biological function?

TRM9 is an S-adenosyl-methionine (SAM)-dependent tRNA methyltransferase that catalyzes the formation of modified nucleosides at the wobble position of specific tRNAs. Its primary function is to methylate the uridine wobble base in specific tRNA species, particularly tRNA ARG(UCU) and tRNA GLU(UUC) .

The methylation reaction catalyzed by TRM9 forms 5-methoxycarbonylmethyluridine (mcm5U) and its thiolated variant 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2U) . These modifications are critical for proper codon-anticodon interactions, specifically enhancing the translation of AGA (arginine) and GAA (glutamic acid) codons .

TRM9 represents the final step in a modification pathway, working with the Trm112 protein to form a functional complex that uses S-adenosyl methionine (SAM) as a methyl donor to complete the formation of mcm5-based modifications .

How do TRM9-catalyzed tRNA modifications affect cellular translation processes?

TRM9-catalyzed modifications play a crucial role in maintaining translational fidelity through several mechanisms:

When TRM9 is absent, cells show increased sensitivity to translation inhibitors like paromomycin and G418, further supporting its critical role in translation fidelity .

What is the relationship between TRM9 and cancer biology?

The human TRM9-like protein (hTRM9L) appears to function as a tumor suppressor, with several lines of evidence supporting this relationship:

• Chromosomal location: The hTRM9L gene maps to the end of chromosome 8, a region commonly lost or silenced in many cancers, including colorectal carcinoma .

• Tumor growth inhibition: Re-expression of hTRM9L in colorectal cancer cell lines (SW620 and HCT116) dramatically inhibits tumor growth in experimental models .

• Growth arrest mechanism: hTRM9L expression induces a senescence-like G0/G1 cell cycle arrest in cancer cells .

• Dependence on methyltransferase activity: The tumor-suppressive function of hTRM9L requires a functional SAM binding domain, suggesting its methyltransferase activity is essential for its anti-cancer effects .

• Therapeutic vulnerability: Cancer cells with loss of hTRM9L show increased sensitivity to aminoglycoside antibiotics, which induce protein damage through misincorporation at specific codons .

These findings suggest a model where loss of hTRM9L in cancer cells leads to reduced tRNA modifications, causing translational infidelity that promotes tumor growth, while restoration of hTRM9L activity inhibits tumorigenicity through multiple mechanisms .

What specific tRNA species are modified by TRM9 and what are the resulting modifications?

TRM9 specifically modifies the wobble uridine position in four tRNA species:

These modifications occur specifically at the wobble position (first anticodon position), enhancing codon recognition and translational accuracy . Quantitative analysis of 23 tRNA modifications in trm9Δ cells showed that only mcm5U and mcm5s2U levels were lower, confirming the specificity of TRM9's catalytic activity .

What is the relationship between TRM9 and the DNA damage response pathway?

TRM9 plays a significant role in the DNA damage response through translational enhancement of key proteins involved in this pathway:

• Enhanced translation of damage response proteins: TRM9 specifically enhances the translation of transcripts enriched with arginine and glutamic acid codons, including critical DNA damage response proteins such as:

  • Ribonucleotide reductase large subunits (Rnr1 and Rnr3)

  • Translation elongation factor 3 (Yef3)

• Codon usage patterns: These damage response proteins share a skewed codon usage pattern favoring the AGA arginine codon, making their translation particularly dependent on TRM9-catalyzed tRNA modifications .

• Sensitivity to DNA damaging agents: Cells deficient in TRM9 display increased sensitivity to DNA damaging agents like MMS (methyl methanesulfonate) and IR (ionizing radiation) .

• Cell cycle progression defect: TRM9-deficient cells show a damage-induced cell cycle progression defect, further linking TRM9 to DNA damage response pathways .

• Translational regulation mechanism: TRM9 represents a novel mechanism to regulate the DNA damage response at the translational level, complementing known transcriptional and post-translational mechanisms .

Researchers identified 425 genes with a unique codon usage pattern linked to TRM9, many of which are involved in the DNA damage response pathway .

How does TRM9 deficiency lead to increased sensitivity to aminoglycoside antibiotics?

TRM9 deficiency creates hypersensitivity to aminoglycoside antibiotics through several interconnected mechanisms:

• Baseline translational infidelity: Without TRM9-catalyzed tRNA modifications, cells already experience decreased translational fidelity, particularly at near-cognate codons .

• Compounded error effects: Aminoglycosides like paromomycin and G418 further promote amino acid misincorporation at near-cognate codons, exacerbating the existing translational errors in TRM9-deficient cells .

• Experimental evidence: Plate-based sensitivity assays demonstrate that trm9Δ cells are significantly more sensitive to paromomycin and G418 compared to wild-type cells .

• Strain independence: This sensitivity phenotype is observed across different yeast strain backgrounds (By4741 and Cen.PK2), confirming the robust nature of this relationship .

• Complementation: Re-expression of TRM9 can rescue the paromomycin-sensitive phenotype, confirming that it's specifically the absence of TRM9 activity causing this sensitivity .

This aminoglycoside sensitivity creates a potential therapeutic vulnerability that could be exploited in cancer cells with decreased hTRM9L expression, as these cells may be selectively killed by aminoglycoside treatment .

What molecular mechanisms connect TRM9-mediated tRNA modifications to translational fidelity?

The molecular basis for TRM9's role in translational fidelity involves several precise mechanisms:

• Enhanced codon discrimination: TRM9-catalyzed mcm5U and mcm5s2U modifications promote the discrimination between cognate and near-cognate codons (e.g., distinguishing AGA from AGU) .

• Stabilized codon-anticodon interactions: These modifications enhance the binding affinity between specific tRNA anticodons and their cognate codons, improving translational accuracy .

• Codon-specific effects: Using dual-luciferase reporter constructs, researchers demonstrated increased arginine misincorporation at specific serine codons (AGC and AGU) in trm9Δ cells, with 1.8-fold and 2.0-fold increases respectively .

• Modification specificity: The effects are highly specific to certain codon-anticodon pairs. For example, arginine misincorporation at UCC or UCG serine codons was similar between wild-type and trm9Δ cells, indicating that not all serine codons are equally affected .

• Protein stress consequences: The translational errors in trm9Δ cells lead to protein errors and activation of unfolded protein and heat shock responses, providing a functional readout of translational infidelity .

This molecular specificity explains why certain transcripts are more affected by TRM9 deficiency than others, creating a mechanism for selective translational control .

What experimental approaches can be used to measure TRM9-mediated effects on translational fidelity?

Several complementary approaches can assess the impact of TRM9 on translational fidelity:

For example, researchers used a dual-luciferase reporter system to demonstrate that trm9Δ cells had a 1.8-fold increase in arginine misincorporation at the AGC serine codon and a 2.0-fold increase at the AGU serine codon compared to wild-type cells .

What controls should be included when studying TRM9 function using antibodies?

When conducting experiments to study TRM9 function using antibodies, several essential controls should be implemented:

• Genetic controls:

  • Wild-type cells as positive control

  • TRM9 knockout/deletion cells (trm9Δ) as negative control

  • Complemented trm9Δ cells expressing TRM9 to verify phenotype rescue

• Antibody specificity controls:

  • Pre-immunization serum control

  • Peptide competition assay to confirm specific binding

  • Cross-reactivity assessment with related methyltransferases

• Functional validation controls:

  • Parallel assessment of known TRM9-dependent tRNA modifications (mcm5U and mcm5s2U)

  • Confirmation of expected phenotypes (e.g., aminoglycoside sensitivity)

  • Monitoring of both protein and mRNA levels to distinguish translational effects

• Experimental system controls:

  • Multiple cell lines or strain backgrounds to ensure robustness

  • Gene dosage experiments (heterozygous vs. homozygous deletions)

  • Alternative methods to confirm antibody-based findings

These controls are critical for establishing the specificity of antibody-based detection of TRM9 and for accurately interpreting experimental results in the context of TRM9's biological functions.

How can researchers quantify TRM9-catalyzed tRNA modifications?

Quantification of TRM9-catalyzed tRNA modifications requires specialized analytical techniques:

• Liquid chromatography-mass spectrometry (LC-MS/MS):

  • The gold standard for quantifying modified nucleosides

  • Allows detection and quantification of mcm5U and mcm5s2U modifications

  • Can assess 20+ different tRNA modifications simultaneously

• Sample preparation procedure:

  • Total tRNA isolation using phenol extraction or commercial kits

  • Enzymatic digestion of tRNA to nucleosides

  • Purification steps to remove contaminants

  • Internal standards addition for accurate quantification

• Analytical considerations:

  • Use of multiple reaction monitoring (MRM) for enhanced specificity

  • Standard curves with synthetic modified nucleosides

  • Normalization to total tRNA amount or canonical nucleosides

• Comparative analysis:

  • Wild-type vs. trm9Δ cells to identify TRM9-dependent modifications

  • Treatment effects (e.g., stress conditions, drug treatments)

  • Correlation with phenotypic outcomes

This approach allowed researchers to definitively show that trm9Δ cells were specifically deficient in only mcm5U and mcm5s2U modifications, with 21 other tRNA modifications remaining unchanged .

What experimental approaches can differentiate between TRM9 and other tRNA modification enzymes?

Distinguishing TRM9 activity from other tRNA modification enzymes requires a multi-faceted approach:

• Modification pathway analysis:

  • TRM9 catalyzes the final methylation step in mcm5U formation

  • Other enzymes (like Elongator complex) are required for earlier steps

  • Sequential enzyme dependency can be mapped through genetic studies

• Substrate specificity:

  • TRM9 specifically modifies wobble uridines in tRNA ARG(UCU) and tRNA GLU(UUC)

  • Other modification enzymes target different positions or tRNA species

  • Comparative analysis of modification patterns can identify enzyme-specific changes

• Genetic approaches:

  • Deletion/mutation of TRM9 vs. other modification enzymes

  • Complementation studies with specific enzyme variants

  • Double mutant analysis to identify epistatic relationships

• Biochemical discrimination:

  • In vitro enzyme assays with purified enzymes and specific tRNA substrates

  • Analysis of co-factor requirements (TRM9 uses SAM as methyl donor)

  • Structural studies of enzyme-substrate complexes

• Functional readouts:

  • Codon-specific translation effects (using reporter systems)

  • Differential sensitivity to translation inhibitors

  • Specific changes in stress response pathway activation

These approaches collectively provide a comprehensive strategy to distinguish TRM9 activity from other tRNA modification enzymes and to understand their respective contributions to translational regulation.

What cell models are most appropriate for studying TRM9 function in cancer research?

Selection of appropriate cell models is critical for studying TRM9 function in cancer research:

Researchers have successfully used SW620 and HCT116 colorectal cancer cell lines engineered to express hTRM9L to demonstrate its tumor suppressor properties . Additionally, yeast systems provide powerful models for dissecting the fundamental mechanisms of TRM9 function, as demonstrated by studies using reporter systems and tRNA modification analysis .

When selecting cell models, researchers should consider:

• Endogenous hTRM9L expression levels

• Genetic background (mutations in related pathways)

• Growth characteristics compatible with planned assays

• Relevant tissue of origin for the cancer type being studied

• Ability to engineer genetic modifications (CRISPR/Cas9 accessibility)

What are the key considerations when designing experiments to study TRM9's role in the DNA damage response?

When investigating TRM9's role in DNA damage response, researchers should consider:

• Selection of DNA damaging agents:

  • MMS and ionizing radiation have established sensitivity phenotypes in trm9Δ cells

  • Different agents target distinct DNA repair pathways

  • Dose-response relationships should be carefully established

• Target protein selection:

  • Focus on proteins with enriched AGA and GAA codons

  • Key targets include ribonucleotide reductase subunits (Rnr1, Rnr3) and Yef3

  • Analyze both mRNA and protein levels to distinguish translational effects

• Cell cycle analysis:

  • TRM9 deficiency causes damage-induced cell cycle progression defects

  • Flow cytometry can assess cell cycle distribution

  • Synchronization methods may help isolate specific cell cycle effects

• Translational efficiency assessment:

  • Reporter constructs with damage response gene coding sequences

  • Polysome profiling to assess translation initiation and elongation

  • Ribosome profiling for codon-specific translation rates

• Integrated pathway analysis:

  • Assess interactions with established DNA damage response factors

  • Analyze both early (sensor) and late (effector) components

  • Consider redundant pathways that may mask TRM9 effects

By carefully considering these factors, researchers can design robust experiments that accurately characterize TRM9's specific contribution to the DNA damage response pathway through its role in translational regulation .